Stockscreener 앱 받기
23.56
2.20%
-0.53
시간 외 거래:
23.56
Evommune Inc 주식(EVMN)의 최신 뉴스
Technical Analysis of Evommune, Inc. (NYSE:EVMN) - TradingView
EVMN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Evommune (EVMN) Insider Trading Activity 2026 - MarketBeat
Analysts Set Expectations for Evommune FY2027 Earnings - MarketBeat
Evommune: Buy Rating Backed by 2026 Catalyst Rich Pipeline and Differentiated MRGPRX2 Dermatology Franchise - TipRanks
This Evommune analyst begins coverage on a bullish note; here are top 5 initiations for Wednesday - MSN
H.C. Wainwright cuts Evommune stock price target on dilution - Investing.com
HC Wainwright Cuts Evommune (NYSE:EVMN) Price Target to $50.00 - MarketBeat
Nvidia To Rally Around 79%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
Evommune (EVMN) Stock Forecast and Price Target 2026 - MarketBeat
This Evommune Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Clear Street initiates Evommune stock with buy rating on drug potential By Investing.com - Investing.com India
Clear Street initiates Evommune stock with buy rating on drug potential - Investing.com Canada
Evommune (NYSE:EVMN) Stock Price Up 7.5%Should You Buy? - MarketBeat
Evommune, Inc. Common Stock (NY: EVMN - The Chronicle-Journal
Evommune, Inc. Common Stock (NYSE:EVMN) Stock Quote - The Chronicle-Journal
Leerink reiterates Evommune stock rating after conference chat - Investing.com Nigeria
Leerink reiterates Evommune stock rating after conference chat By Investing.com - Investing.com Canada
RBC Capital initiates Evommune stock with outperform rating By Investing.com - Investing.com Canada
RBC Capital initiates Evommune stock with outperform rating - Investing.com
Evommune, Inc. (NYSE:EVMN) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
1 Under‑the‑Radar Biotech to Buy for Potential 10X Growth in the Next Decade - The Globe and Mail
Evommune initiated with an Outperform at RBC Capital - TipRanks
Evommune (NYSE:EVMN) Trading Down 6.7%Here's What Happened - MarketBeat
Evommune, Inc. (EVMN) Receives a Rating Update from a Top Analyst - The Globe and Mail
Evommune (NYSE:EVMN) Trading 6.9% HigherTime to Buy? - MarketBeat
Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlight - PharmiWeb.com
Evommune Reports Q4 2025 Results and Pipeline Progress - TipRanks
Evommune reports Q4 EPS ($1.43), consensus (84c) - TipRanks
Evommune, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights - The Joplin Globe
This Biotech Stock Nearly Doubled In Value Today Morning – What’s Driving Investor Optimism? - Stocktwits
Evommune, Inc. announced that it has received $125.300499 million in funding - marketscreener.com
Evommune, Inc.: Lead in MRGPRX2 Modulation and Differentiated EVO756 Profile Support Buy Rating - TipRanks
EVMN Technical Analysis & Stock Price Forecast - Intellectia AI
Evommune (NYSE:EVMN) Trading Down 10.2%Time to Sell? - MarketBeat
Evommune (EVMN) Price Target Increased by 37.87% to 55.08 - Nasdaq
Evommune CEO Luis Peña Reveals What’s Behind Company’s Post-IPO Success - Yahoo Finance
What is the current Price Target and Forecast for Evommune Inc. (EVMN) - Zacks Investment Research
Analysts Offer Insights on Healthcare Companies: Evommune, Inc. (EVMN) and Charles River Labs (CRL) - The Globe and Mail
Evommune (NYSE:EVMN) Trading Down 7.4%Time to Sell? - MarketBeat
Morgan Stanley Maintains Overweight on Evommune (EVMN) Feb 18 2026 - Meyka
Eczema Pipeline 2026 Outlook: 100+ Clinical Assets and 3 Key Late-Stage Candidates to Watch, analyses DelveInsight - openPR.com
EVMN Should I Buy - Intellectia AI
Evommune Announces $125 Million Private Placement - The AI Journal
Evommune announces $125 million private placement - The Pharma Letter
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet - Finviz
Benzinga Stock Whisper Index Analysis - Intellectia AI
Evommune raises $125 million in private placement to fund R&D By Investing.com - Investing.com Canada
1.20%
0.06%
자본화:
|
볼륨(24시간):